These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 8198374)

  • 1. Hirudin: clinical potential of a thrombin inhibitor.
    Johnson PH
    Annu Rev Med; 1994; 45():165-77. PubMed ID: 8198374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease.
    Cannon CP; Maraganore JM; Loscalzo J; McAllister A; Eddings K; George D; Selwyn AP; Adelman B; Fox I; Braunwald E
    Am J Cardiol; 1993 Apr; 71(10):778-82. PubMed ID: 8456753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis--comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban.
    Finkle CD; St Pierre A; Leblond L; Deschenes I; DiMaio J; Winocour PD
    Thromb Haemost; 1998 Feb; 79(2):431-8. PubMed ID: 9493603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective use of BCH-2763, a new potent injectable direct thrombin inhibitor, in combination with tissue plasminogen activator (tPA) in a rat arterial thrombolysis model.
    Deschênes I; Finkle CD; Winocour PD
    Thromb Haemost; 1998 Jul; 80(1):186-91. PubMed ID: 9684808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hirudin and hirudin analogues as new anticoagulant agents.
    Pineo GF; Hull RD
    Curr Opin Hematol; 1995 Sep; 2(5):380-5. PubMed ID: 9372023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Unstable angina pectoris: coagulation disorder and its therapy].
    Meyer BJ
    Praxis (Bern 1994); 1995 Feb; 84(8):232-8. PubMed ID: 7886362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-clinical and clinical studies on Hirulog: a potent and specific direct thrombin inhibitor.
    Maraganore JM
    Adv Exp Med Biol; 1993; 340():227-36. PubMed ID: 8154339
    [No Abstract]   [Full Text] [Related]  

  • 8. Inhibition of heparin-resistant microarterial thrombosis by recombinant hirudin: a specific thrombin inhibitor.
    Arnljots B; Bergqvist D
    Plast Reconstr Surg; 1995 Apr; 95(5):894-900. PubMed ID: 7708874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leeches to hirulogs and other thrombin-directed antithrombotics.
    Fenton JW
    Hematol Oncol Clin North Am; 1992 Oct; 6(5):1121-9. PubMed ID: 1400076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological effects of a novel recombinant hirudin, CX-397, in vivo and in vitro: comparison with recombinant hirudin variant-1, heparin, and argatroban.
    Komatsu Y; Inoue Y; Goto Y; Fukazawa T; Hayashi H
    Thromb Haemost; 1999 Feb; 81(2):250-5. PubMed ID: 10064001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of antithrombin III-independent thrombin inhibitors and heparin on fibrin accretion onto fibrin-coated polyethylene.
    Rubens FD; Weitz JI; Brash JL; Kinlough-Rathbone RL
    Thromb Haemost; 1993 Feb; 69(2):130-4. PubMed ID: 8456425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin.
    Bates SM; Weitz JI
    Am J Cardiol; 1998 Oct; 82(8B):12P-18P. PubMed ID: 9809887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct thrombin inhibitors for non-ST-segment elevation acute coronary syndromes: what, when, and where?
    Lincoff AM
    Am Heart J; 2003 Oct; 146(4 Suppl):S23-30. PubMed ID: 14564303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct effects of recombinant desulfatohirudin (Revasc) and heparin on plasma levels of fibrinopeptide A and prothrombin fragment F1.2 in unstable angina. A multicenter trial.
    Rao AK; Sun L; Chesebro JH; Fuster V; Harrington RA; Schwartz D; Gallo P; Matos D; Topol EJ
    Circulation; 1996 Nov; 94(10):2389-95. PubMed ID: 8921778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hirudin (desirudin) and Hirulog (bivalirudin) in acute ischaemic syndromes and the rationale for the Hirulog/Early Reperfusion Occlusion (HERO-2) Study.
    White HD; Ellis CJ; French JK; Aylward P
    Aust N Z J Med; 1998 Aug; 28(4):551-4. PubMed ID: 9777138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful treatment of heparin-associated thrombocytopenia and thrombosis using Hirulog.
    Chamberlin JR; Lewis B; Leya F; Wallis D; Messmore H; Hoppensteadt D; Walenga JM; Moran S; Fareed J; McKiernan T
    Can J Cardiol; 1995 Jun; 11(6):511-4. PubMed ID: 7780873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hirulog in the treatment of unstable angina. Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial.
    Fuchs J; Cannon CP
    Circulation; 1995 Aug; 92(4):727-33. PubMed ID: 7641350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Direct thrombin antagonists].
    Lankes W; Fleischer K; Gulba DC
    Herz; 2001 Apr; 26 Suppl 1():46-52. PubMed ID: 11349627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct thrombin inhibitors as adjuncts to thrombolytic therapy.
    French JK; White HD
    Curr Cardiol Rep; 1999 Sep; 1(3):184-91. PubMed ID: 10980840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hirudin, a new therapeutic tool?
    Bichler J; Fritz H
    Ann Hematol; 1991 Aug; 63(2):67-76. PubMed ID: 1912033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.